LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. (23rd October 2018) - Javle, M; Kelley, R K; Roychowdhury, S; Weiss, K H; Abou-Alfa, G K; Macarulla, T; Sadeghi, S; Waldschmidt, D; Zhu, A X; Goyal, L; Borad, M; Yong, W P; et al.